Funded Biotechnology Startups in Seattle
Disclosed biotech financing rounds in Seattle (50 rows shown) span 2021-08-10 to 2026-08-12, with 2026 accounting for 9 of the entries.
Disclosed biotech financing rounds in Seattle (50 rows shown) span 2021-08-10 to 2026-08-12, with 2026 accounting for 9 of the entries. The disclosed amounts also show a sharp right tail: Callio Therapeutics raised $187M on 2025-03-03, and that largest figure dwarfs the next-largest disclosed round (Tune Therapeutics at $175M on 2025-01-12), while still keeping multiple mega-rounds clustered in the same high range ($150M–$157M for Alpine Immune Sciences on 2023-11-06 and Outpace Bio on 2024-08-01; $125M for Adaptive Biotechnologies on 2022-09-12). Stage labeling skews heavily toward classification gaps, with Series Unknown appearing 23 times out of 50 rows, including large disclosed rounds such as Sana Biotechnology’s $69M (2026-05-15) and Bonum Therapeutics’ $27M (2026-04-17). The list also contains smaller outliers at the low end of disclosed amounts, including $100K for Pacific Northwest Research Institute on 2023-08-10, alongside debt and grant instruments like Adaptive Biotechnologies’ $125M Post-IPO Debt (2022-09-12) and Blue Marble Space Institute of Science’s undisclosed Grant (2022-07-27).
Most recent rounds
50 of 588 more funded startups
This page shows the 50 most recent rounds (back to Aug 2021). The full 58-company history for this listing opens on a FundedIQ plan.
Unlock all 58 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
What does the distribution of disclosed deal sizes look like, and which entries anchor the top end?
The disclosed peak is Callio Therapeutics at $187M (2025-03-03), followed by Tune Therapeutics at $175M (2025-01-12), with several other top-tier disclosed rounds in the same $150M–$157M band: GentiBio $157M (2021-08-11) and Alpine Immune Sciences $150M (2023-11-06). At the low end, the smallest disclosed amount is $100K for Pacific Northwest Research Institute (2023-08-10).
Is there a stage-label mix that dominates, and does it correlate with large disclosed rounds?
Series Unknown appears most frequently (23 of 50 rows), including materially sized disclosed rounds like Sana Biotechnology ($69M on 2026-05-15), Aptevo Therapeutics ($2M on 2026-06-30), and Bonum Therapeutics ($27M on 2026-04-17). Meanwhile, labeled stages do surface large checks too, such as Avalyn Pharma’s Series D $100M (2025-07-22) and InduPro’s Series B $77M (2026-08-12).
Which financing formats show up as outliers compared with standard equity rounds?
Debt and non-equity instruments appear, including Adaptive Biotechnologies’ Post-IPO Debt $125M (2022-09-12) and Visus Therapeutics’ Debt Financing $20M (2021-08-10). The listing also includes a Grant with an undisclosed amount for Blue Marble Space Institute of Science (2022-07-27), plus additional undisclosed entries like RareCyte (undisclosed, 2022-11-03).
How concentrated are these rounds over time—especially near the most recent months shown?
The table covers 2021-08-10 through 2026-08-12, with the most recent entry being InduPro’s Series B $77M on 2026-08-12. The years are fairly even across the window shown (2021: 5; 2022: 10; 2023: 10; 2024: 7; 2025: 9; 2026: 9), so concentration is more visible in “top end” months than in any single year.
Are there any recurring naming patterns by city (or are these all uniformly Seattle)?
Every listed company is shown with Seattle, Washington, United States, and Seattle appears 50 times with every company in the dataset. That means there is no cross-city comparison to be made inside this specific listing; the main variation is in stage label, instrument type, and disclosed amount.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.